Molecular Partners Ag (MOLN) Asset Utilization Ratio (2021 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Asset Utilization Ratio of 0.07 for Q1 2026, down 762.91% year-over-year from 0.01 in Q1 2025, and down 58.86% quarter-over-quarter from 0.04 in Q4 2025.
Molecular Partners Ag (MOLN) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Asset Utilization Ratio for 6 consecutive years, with 0.07 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Utilization Ratio fell 762.91% year-over-year to 0.07; the TTM figure through Mar 2026 stood at 0.07 (down 762.91% YoY), while the FY2025 annual figure was 0.0, up 2747.4% from the prior year.
- Asset Utilization Ratio fell to 0.07 in Q1 2026 per MOLN's latest filing, from 0.04 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 1.3 in Q4 2022 and bottomed at 0.07 in Q1 2026.
- Historically, Asset Utilization Ratio has averaged 0.32 across 5 years, with a median of 0.03 in 2023.
- Annual changes were most pronounced in 2025 — Asset Utilization Ratio soared 13336.91% — and 2026, when it slumped 762.91%.
- Molecular Partners Ag's Asset Utilization Ratio stood at 1.3 in 2022, then plunged by 97.95% to 0.03 in 2023, then sank by 67.02% to 0.01 in 2024, then sank by 573.22% to 0.04 in 2025, then sank by 58.86% to 0.07 in 2026.
- Business Quant data shows MOLN's Asset Utilization Ratio at 0.07 in Q1 2026, 0.04 in Q4 2025, and 0.69 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 0.13 |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.07 |
| Dec 31, 2025 | -0.04 |
| Sep 30, 2025 | 0.69 |
| Jun 30, 2025 | 0.01 |
| Mar 31, 2025 | 0.01 |
| Dec 31, 2024 | 0.01 |
| Sep 30, 2024 | 0.01 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.03 |
| Sep 30, 2023 | 0.03 |
| Jun 30, 2023 | 0.04 |
| Mar 31, 2023 | 0.04 |
| Dec 31, 2022 | 1.30 |
| Sep 30, 2022 | 1.24 |
| Jun 30, 2022 | 1.06 |
| Mar 31, 2022 | 1.05 |
| Dec 31, 2021 | -0.09 |